Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PGNY Stock Forecast 2025-2026
$22.76
Current Price
$1.96B
Market Cap
Buy 4
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to PGNY Price Targets
+49.4%
To High Target of $34.00
+18.6%
To Median Target of $27.00
+1.1%
To Low Target of $23.00
PGNY Price Momentum
+6.5%
1 Week Change
+3.9%
1 Month Change
-29.0%
1 Year Change
+31.9%
Year-to-Date Change
-32.7%
From 52W High of $33.84
+70.0%
From 52W Low of $13.39
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Progyny (PGNY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PGNY and similar high-potential opportunities.
Latest PGNY Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, PGNY has a neutral consensus with a median price target of $27.00 (ranging from $23.00 to $34.00). The overall analyst rating is Buy (7.6/10). Currently trading at $22.76, the median forecast implies a 18.6% upside. This outlook is supported by 4 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Stephanie Davis at SVB Leerink, projecting a 49.4% upside. Conversely, the most conservative target is provided by Richard Close at Canaccord Genuity, suggesting a 1.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PGNY Analyst Ratings
4
Buy
6
Hold
0
Sell
PGNY Price Target Range
Low
$23.00
Average
$27.00
High
$34.00
Current: $22.76
Latest PGNY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PGNY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2025 | BTIG | David Larsen | Buy | Upgrade | $28.00 |
| Feb 28, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $23.00 |
| Feb 11, 2025 | B of A Securities | Michael Cherny | Buy | Maintains | $25.00 |
| Jan 28, 2025 | JP Morgan | Anne Samuel | Neutral | Maintains | $23.00 |
| Dec 2, 2024 | JP Morgan | Anne Samuel | Neutral | Downgrade | $17.00 |
| Nov 14, 2024 | Barclays | Sarah James | Overweight | Maintains | $17.00 |
| Nov 13, 2024 | Canaccord Genuity | Richard Close | Hold | Maintains | $17.00 |
| Nov 13, 2024 | B of A Securities | Michael Cherny | Buy | Maintains | $21.00 |
| Nov 13, 2024 | Truist Securities | Jailendra Singh | Hold | Downgrade | $19.00 |
| Oct 1, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $25.00 |
| Sep 20, 2024 | Canaccord Genuity | Richard Close | Hold | Maintains | $18.00 |
| Sep 19, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $25.00 |
| Sep 19, 2024 | Leerink Partners | Michael Cherny | Market Perform | Maintains | $21.00 |
| Sep 19, 2024 | JMP Securities | Constantine Davides | Market Perform | Downgrade | $0.00 |
| Sep 19, 2024 | Jefferies | Glen Santangelo | Buy | Maintains | $24.00 |
| Sep 19, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $26.00 |
| Sep 19, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $22.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $37.00 |
| Aug 19, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $31.00 |
| Aug 7, 2024 | Leerink Partners | Michael Cherny | Market Perform | Downgrade | $25.00 |
Progyny Inc. (PGNY) Competitors
The following stocks are similar to Progyny based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Progyny Inc. (PGNY) Financial Data
Progyny Inc. has a market capitalization of $1.96B with a P/E ratio of 39.9x. The company generates $1.17B in trailing twelve-month revenue with a 4.7% profit margin.
Revenue growth is +10.6% quarter-over-quarter, while maintaining an operating margin of +5.3% and return on equity of +11.1%.
Valuation Metrics
Market Cap
$1.96B
Enterprise Value
$1.74B
P/E Ratio
39.9x
PEG Ratio
29.9x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+10.6%
Gross Margin
+21.3%
Operating Margin
+5.3%
Net Margin
+4.7%
EPS Growth
-21.8%
Financial Health
Cash/Price Ratio
+11.7%
Current Ratio
2.8x
Debt/Equity
4.6x
ROE
+11.1%
ROA
+6.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Progyny Inc. (PGNY) Business Model
About Progyny Inc.
What They Do
Offers fertility benefits management solutions.
Business Model
Progyny Inc. generates revenue by partnering with large employers to provide comprehensive fertility and family-building benefits as part of their employee health plans. The company enhances reproductive health by offering a range of services including IVF and fertility preservation, thus enabling employers to manage their healthcare costs while improving employee satisfaction and outcomes.
Additional Information
Progyny is at the forefront of a growing demand for fertility treatments, positioning itself as a crucial player in the healthcare and insurance sectors. Its technology-driven solutions not only streamline fertility care but also contribute to corporate wellness initiatives, making it a significant asset for businesses looking to enhance employee benefits.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
675
CEO
Mr. Peter Anevski CPA
Country
United States
IPO Year
2019
Website
www.progyny.comProgyny Inc. (PGNY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Progyny (PGNY) is Poised to Beat Earnings Estimates Again
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 21, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Progyny, Inc. (Nasdaq: PGNY) will announce its Q1 2025 financial results on May 8, 2025, after market close.
Why It Matters
Progyny's upcoming financial results could impact its stock price and investor sentiment, indicating growth or challenges in the women's health sector and family planning market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Progyny (PGNY) is expected to potentially exceed earnings expectations in its upcoming quarterly report, supported by a strong history of earnings surprises.
Why It Matters
Progyny's strong earnings surprise history and favorable indicators suggest potential for positive quarterly results, which could boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The company has made leadership additions to enhance its capacity to scale operations, focusing on women's health and family building services.
Why It Matters
Leadership changes signal potential for growth and improved operational efficiency, enhancing the company's market position in women's health and family planning, which may drive investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Progyny is enhancing discussions on fertility access and coverage, aiming to support millions facing family building challenges. This could signal growth opportunities in the fertility services sector.
Why It Matters
Progyny's focus on fertility access highlights a growing market trend, potentially increasing demand for its services and boosting revenue, attracting investor interest in the evolving healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Progyny, Inc. (Nasdaq: PGNY) and The Broken Brown Egg launched the 2025 Awareness, Hope, and Activism Grant, continuing their partnership to support BIPOC individuals facing infertility.
Why It Matters
Progyny's partnership with The Broken Brown Egg highlights a commitment to social responsibility and community support, potentially enhancing brand reputation and attracting socially conscious investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
In-person and virtual doula care services are now available for employers and health plans, aiming to close care gaps and enhance health outcomes.
Why It Matters
The introduction of in-person and virtual doula services may enhance healthcare offerings, potentially increasing demand for related health plans and improving overall market growth in healthcare sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PGNY Stock
What is Progyny Inc.'s (PGNY) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Progyny Inc. (PGNY) has a median price target of $27.00. The highest price target is $34.00 and the lowest is $23.00.
Is PGNY stock a good investment in 2025?
According to current analyst ratings, PGNY has 4 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $22.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PGNY stock?
Wall Street analysts predict PGNY stock could reach $27.00 in the next 12 months. This represents a 18.6% increase from the current price of $22.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Progyny Inc.'s business model?
Progyny Inc. generates revenue by partnering with large employers to provide comprehensive fertility and family-building benefits as part of their employee health plans. The company enhances reproductive health by offering a range of services including IVF and fertility preservation, thus enabling employers to manage their healthcare costs while improving employee satisfaction and outcomes.
What is the highest forecasted price for PGNY Progyny Inc.?
The highest price target for PGNY is $34.00 from Stephanie Davis at SVB Leerink, which represents a 49.4% increase from the current price of $22.76.
What is the lowest forecasted price for PGNY Progyny Inc.?
The lowest price target for PGNY is $23.00 from Richard Close at Canaccord Genuity, which represents a 1.1% increase from the current price of $22.76.
What is the overall PGNY consensus from analysts for Progyny Inc.?
The overall analyst consensus for PGNY is neutral. Out of 11 Wall Street analysts, 4 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $27.00.
How accurate are PGNY stock price projections?
Stock price projections, including those for Progyny Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 4:45 AM UTC